Case Reports Gynecologic oncology reports. 2016 Nov 6:18:42-44. doi: 10.1016/j.gore.2016.11.001 Q31.32025

Response to sunitinib (Sutent) in chemotherapy refractory clear cell ovarian cancer

索坦(Sutent)治疗化疗无效的透明细胞卵巢癌的效果响应 翻译改进

作者单位 +展开

DOI: 10.1016/j.gore.2016.11.001 PMID: 27872893

摘要 Ai翻译

Copyright © Gynecologic oncology reports. 中文内容为AI机器翻译，仅供参考！

相关内容

• [Clear cell ovarian carcinoma]

  卵巢透明细胞癌

  P Morf

  Gynakologische Rundschau. 1979;19(3):139-44.

• Clear cell ovarian cancer and endometriosis: is there a relationship?

  透明细胞卵巢癌和子宫内膜异位症的关系探讨

  Maria Szubert et al.

  Przeglad menopauzalny = Menopause review. 2016 Jun;15(2):85-9.

• Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer

  免疫抑制途径基因多态性与卵巢透明细胞癌发病风险的关联研究发现TGFBR2基因多态性是影响卵巢透明细胞癌发病风险的因素之一

  Shalaka S Hampras et al.

  Oncotarget. 2016 Oct 25;7(43):69097-69110.

• Clear cell ovarian adenocarcinoma

  透明细胞卵巢腺癌

  M Yoonessi et al.

  Journal of surgical oncology. 1984 Dec;27(4):289-97.

• The Tumor Microenvironment of Clear-Cell Ovarian Cancer

  透明细胞卵巢癌的肿瘤微环境

  Michael-John Devlin et al.

  Cancer immunology research. 2022 Nov 2;10(11):1326-1339.

• Multi-omics Uncovering Different Faces of Clear Cell Ovarian Cancer

  多组学揭示卵巢透明细胞癌的不同面相

  Stephanie Lheureux

  Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Nov 14;28(22):4838-4839.

• Early-stage clear cell ovarian cancer compared to high-grade histological subtypes: An outcome exploratory analysis in two oncology centers

  早期透明细胞卵巢癌与高级别组织亚型的比较：两个肿瘤中心的结果探索性分析

  Lorenzo Ceppi et al.

  Gynecologic oncology. 2021 Jan;160(1):64-70.

• H2Bub1 loss is an early contributor to clear cell ovarian cancer progression

  H2Bub1丢失是透明细胞卵巢癌进展的早期促进因素

  Adam J Ferrari et al.

  JCI insight. 2023 Jun 22;8(12):e164995.